Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market
The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly expanding into the realm of oral...
Search results for "Novo Nordisk"
High Efficacy and Increased Convenience: The Three Obesity Drugs Awaiting FDA Approval
Since the World Health Organization recommended the use of obesity medications for adults last December, the market is expected to heat up even...
‘Singapore Is the Bridge, Not the Destination’: Novo Holdings Connects Asian Biotech to Global Capital
Global life sciences investment firm Novo Holdings is bringing its proven European biotech company-building playbook to...
Do Wegovy and Mounjaro Count as Doping? WADA Monitors GLP-1 Drugs in Sports
GLP-1 (glucagon-like peptide-1) class medications, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, are...
Considering Wegovy for Weight Loss? South Korea's Drug Safety Ministry Warns It Is Not for Everyone
South Korea’s Ministry of Food and Drug Safety issued a strong warning on July 8 against the misuse and abuse of GLP-1...
South Korean Biotechs Race to Conquer the Untapped Global MASH Market
Fat accumulation in the liver can trigger severe inflammation even in individuals who completely abstain from alcohol.
GLP-1 Weight-Loss Drugs: Potential Metabolic Instability Linked to Long-Term Use
A new study suggests that the long-term administration of GLP-1 receptor agonists—the class of anti-obesity medications...
Sam Chun Dang Pharm Secures Exclusive U.S. Licensing Deal for Oral Obesity and Diabetes Treatment
Sam Chun Dang Pharm has entered into a significant license-out agreement with an undisclosed U. S.
Can Wegovy and Mounjaro Reduce Cancer Risk?
Global obesity experts have proposed a large-scale, long-term follow-up study to verify whether the use of modern...
HK inno.N’s ‘Ecnoglutide’: Can a Late Entrant’s “Hidden Card” Reshape the Obesity Market?
HK inno.N is fast-tracking the South Korean launch of ecnoglutide, a GLP-1 receptor agonist licensed from China’s...